Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer

[1]  C. Morrison,et al.  Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts , 2016, Oncotarget.

[2]  A. Wyatt,et al.  Not all NOTCH Is Created Equal: The Oncogenic Role of NOTCH2 in Bladder Cancer and Its Implications for Targeted Therapy , 2016, Clinical Cancer Research.

[3]  Jianmin Zhang,et al.  YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage , 2015, Oncogene.

[4]  L. Vermeulen,et al.  ER-Stress-Induced Differentiation Sensitizes Colon Cancer Stem Cells to Chemotherapy. , 2015, Cell reports.

[5]  Seong-Jin Kim,et al.  Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer , 2015, Oncotarget.

[6]  S. Shi,et al.  MSC Transplantation Improves Osteopenia via Epigenetic Regulation of Notch Signaling in Lupus. , 2015, Cell metabolism.

[7]  M. Beckmann,et al.  Abstract B32: Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses , 2016 .

[8]  Trevor J Pugh,et al.  DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts , 2015, Cell.

[9]  Xiaoyuan Xu,et al.  γ-Secretase inhibitor inhibits bladder cancer cell drug resistance and invasion by reducing epithelial-mesenchymal transition. , 2015, Molecular medicine reports.

[10]  J. Maciejewski,et al.  Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. , 2015, The Journal of clinical investigation.

[11]  A. Valencia,et al.  NOTCH pathway inactivation promotes bladder cancer progression. , 2015, The Journal of clinical investigation.

[12]  Zhenyi Liu,et al.  The intracellular domains of Notch1 and Notch2 are functionally equivalent during development and carcinogenesis , 2015, Development.

[13]  D. Matei,et al.  The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer , 2014, Clinical Cancer Research.

[14]  Xu Zhang,et al.  Notch-1 regulates proliferation and differentiation of human bladder cancer cell lines by inhibiting expression of Krüppel-like factor 4. , 2014, Oncology reports.

[15]  C. Cordon-Cardo,et al.  Bladder cancers arise from distinct urothelial sub-populations , 2014, Nature Cell Biology.

[16]  A. Scorilas,et al.  A new tumor suppressor role for the Notch pathway in bladder cancer , 2014, Nature Medicine.

[17]  W. Schulz,et al.  Canonical Notch signalling is inactive in urothelial carcinoma , 2014, BMC Cancer.

[18]  T. Yen,et al.  IL-6-stimulated CD11b+CD14+HLA-DR− myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus , 2014, Oncotarget.

[19]  A. Qin,et al.  Targeting Notch1 signaling pathway positively affects the sensitivity of osteosarcoma to cisplatin by regulating the expression and/or activity of Caspase family , 2014, Molecular Cancer.

[20]  P. Saftig,et al.  Regulated Proteolysis of NOTCH2 and NOTCH3 Receptors by ADAM10 and Presenilins , 2014, Molecular and Cellular Biology.

[21]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[22]  V. Nizet,et al.  Cholera toxin disrupts barrier function by inhibiting exocyst-mediated trafficking of host proteins to intestinal cell junctions. , 2013, Cell host & microbe.

[23]  K. Tsui,et al.  Mechanisms by Which Interleukin-6 Attenuates Cell Invasion and Tumorigenesis in Human Bladder Carcinoma Cells , 2013, BioMed research international.

[24]  Solomon H. Snyder,et al.  Erratum: Inositol polyphosphate multikinase is a coactivator of p53-mediated transcription and cell death (Science Signaling (2013) 6: 273 (er1) Doi: 10.1126/scisignal.6273er1) , 2013 .

[25]  Miao-Fen Chen,et al.  IL-6 Expression Regulates Tumorigenicity and Correlates with Prognosis in Bladder Cancer , 2013, PloS one.

[26]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[27]  Martha L Slattery,et al.  JAK/STAT/SOCS‐signaling pathway and colon and rectal cancer , 2013, Molecular carcinogenesis.

[28]  E. R. Andersson,et al.  Non-canonical Notch signaling activates IL-6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKKα/IKKβ , 2012, Oncogene.

[29]  R. Momparler,et al.  Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy , 2013, Clinical Epigenetics.

[30]  Y. Nakanishi,et al.  IL-6 induced by double-stranded RNA augments allergic inflammation via suppression of Foxp3+ T-cell/IL-10 axis. , 2012, American journal of respiratory cell and molecular biology.

[31]  A. Gudkov,et al.  p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs , 2012, Proceedings of the National Academy of Sciences.

[32]  Jin Yang,et al.  Cancer stem-like cells contribute to cisplatin resistance and progression in bladder cancer. , 2012, Cancer letters.

[33]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[34]  D. Matei,et al.  Epigenetic resensitization to platinum in ovarian cancer. , 2012, Cancer research.

[35]  J. Catto,et al.  Molecular mechanisms of cisplatin resistance in bladder cancer , 2012, Expert review of anticancer therapy.

[36]  T. Palaga,et al.  Direct regulation of interleukin-6 expression by Notch signaling in macrophages , 2011, Cellular and Molecular Immunology.

[37]  Daniel T. Fisher,et al.  IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. , 2011, The Journal of clinical investigation.

[38]  J. Maciejewski,et al.  p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia , 2011, Leukemia.

[39]  M. Kirschner,et al.  Optimizing Optical Flow Cytometry for Cell Volume-Based Sorting and Analysis , 2011, PloS one.

[40]  J. Campisi,et al.  The senescence-associated secretory phenotype: the dark side of tumor suppression. , 2010, Annual review of pathology.

[41]  M. Maitland,et al.  Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  P. Linsley,et al.  Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application , 2010, Nature Reviews Drug Discovery.

[43]  D. Solís.  US Food and Drug Administration , 2010 .

[44]  J. Campisi,et al.  Persistent DNA damage signaling triggers senescence-associated inflammatory cytokine secretion , 2009, Nature Cell Biology.

[45]  Xin Ma,et al.  Association of low expression of notch-1 and jagged-1 in human papillary bladder cancer and shorter survival. , 2008, The Journal of urology.

[46]  M. Grever,et al.  Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  R. Dahiya,et al.  Epigenetic Inactivation of Wnt Inhibitory Factor-1 Plays an Important Role in Bladder Cancer through Aberrant Canonical Wnt/β-Catenin Signaling Pathway , 2006, Clinical Cancer Research.

[48]  Sergio Ricci,et al.  Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Richard Pazdur,et al.  FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. , 2005, The oncologist.

[50]  Arie Perry,et al.  Notch1 and Notch2 Have Opposite Effects on Embryonal Brain Tumor Growth , 2004, Cancer Research.

[51]  K. Raj,et al.  The role of Notch in tumorigenesis: oncogene or tumour suppressor? , 2003, Nature Reviews Cancer.

[52]  Yao-Tseng Chen,et al.  NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. , 2003, Cancer research.

[53]  Rolf Rossaint,et al.  Activation of STAT3 by IL-6 and IL-10 in Primary Human Macrophages Is Differentially Modulated by Suppressor of Cytokine Signaling 3 1 , 2003, The Journal of Immunology.

[54]  M. Dettke,et al.  Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia. , 2002, Blood.

[55]  J. Brooks,et al.  GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. , 2001, The American journal of pathology.

[56]  Freddy Radtke,et al.  Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation , 2001, The EMBO journal.

[57]  D. Lane,et al.  Cell differentiation and chemotherapy influence p53 and Mdm2 immunoreactivity in human HT29 colon cancer cells grown in scid mice. , 2001, Cancer letters.

[58]  J. Catania,et al.  Involvement of Rb family proteins, focal adhesion proteins and protein synthesis in senescent morphogenesis induced by hydrogen peroxide. , 2000, Journal of cell science.

[59]  J. Harcourt,et al.  Interferon-alpha synergistically enhances induction of interleukin-6 by double stranded RNA in HeLa cells. , 2000, European journal of biochemistry.

[60]  P. Jones,et al.  Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines. , 1998, Cancer research.

[61]  T. Norwood,et al.  Cell enlargement: One possible mechanism underlying cellular senescence , 1989, Journal of cellular physiology.